Metastatic Melanoma

Provectus announces a second group of patients treated in phase I trial of PV-10

Published in Cancer Weekly, June 12th, 2006

Provectus Pharmaceuticals, Inc. (PVCT) announced that a second group of subjects has been treated in the company's phase I clinical trial of PV-10 (also known as Provecta) for ablation of metastatic melanoma, an aggressive and often fatal form of skin cancer.

Treatment with PV-10 was well tolerated by all subjects, with no evidence of systemic or serious local side effects. Most subjects have exhibited evidence of efficacy, ranging from tumor shrinkage to complete ablation. Several also exhibited subsequent shrinkage of untreated tumors, a response characteristic of the "bystander effect." These results achieve the primary study endpoints of safety and preliminary...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry